Janssen-Cilag Pty Ltd have advised that INCIVO® (Telaprevir) will be removed from the Pharmaceutical Benefits Scheme and deregistered on 1 September 2015 due to the availability of other direct-acting anti-virals (DAAs) as alternatives.
Telaprevir is a first generation direct-acting anti-viral medication that is used in combination with peg-interferon and ribavirin to treat hepatitis C genotype 1. Telaprevir has been replaced within the clinical setting by OLYSIO® (simeprevir), a second generation DAA with an improved safety and tolerability profile.
Please refer to the INCIVO® Product Information (until I September 2015) should you need any information on this product.
If you have any questions regarding the removal of INCIVO® from the PBS or the deregistration, please contact Janssen Medical Information on 1800 226 334 or email@example.com.